N4 Pharma plc has successfully completed the first in vivo study of orally delivered Nuvec using its lead program N4 101, an orally administered anti-inflammatory treatment for inflammatory bowel disease (IBD).
Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to prevent the accumulation of substances that the body can’t process. Current treatments mainly focus on managing symptoms and metabolite levels, and do not always prevent the progressive deterioration caused by mutations associated with the condition. However, emerging gene therapies hold promise for transforming these diseases by targeting their underlying causes, as presented in the oral abstract session, “Gene and cell therapy for metabolic diseases” of the ongoing 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) meeting in New Orleans.
Kymera Therapeutics Inc. has announced a new oral IRF5 degrader program with potential to treat immuno-inflammatory diseases, such as lupus, Sjögren’s syndrome, rheumatoid arthritis and inflammatory bowel disease.
Beijing QL Biopharmaceutical Co. Ltd. has presented preclinical data on their GLP-1/GDF15 dual agonist QL-1005 for the potential treatment of inflammation and fibrosis in murine models of metabolic dysfunction-associated steatohepatitis (MASH) and chemically induced liver fibrosis.
Immunity is not a function most people particularly associate with the liver. But because of its connection to the gut, the liver is exposed to bacterial metabolites as few other organs are. And when either the liver or the gut is not functioning well, it can adversely affect immunity as well. The liver is connected to the gut via both the biliary system and the portal vein. Those two conduits allow metabolites from the gut microbiome to influence what’s going on in the liver. Both liver and gut damage can affect this communication for the worse. And surprisingly, one of the consequences is immune dysfunction.
Interleukin-10 (IL-10) is an immunoregulatory cytokine produced by a variety of immune cells, including type 1 regulatory T cells and macrophages, as well as nonimmune cells such as epithelial cells and fibroblasts.
Scientists at Arontier Co. Ltd. and Korea Research Institute of Chemical Technology have disclosed ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2; autotaxin) inhibitors reported to be useful for the treatment of hepatic steatosis, hepatic fibrosis, cirrhosis, liver failure, hepatitis and liver cancer, among others.
Equillium Inc. is advancing EQ-504, a potent aryl hydrocarbon receptor (AhR) modulator acquired through the acquisition of Ariagen Inc., a company that was majority owned by Equillium’s largest investor, Decheng Capital.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern, with an estimated prevalence of around 25% worldwide. This chronic liver condition is characterized by lipid deposition in the liver, which can lead to inflammation, scarring and even liver cancer if left untreated.
RSS
